Kyntra Bio, Inc. (KYNB) - Total Liabilities
Based on the latest financial reports, Kyntra Bio, Inc. (KYNB) has total liabilities worth $115.12 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Kyntra Bio, Inc. growing its equity to track the company's year-over-year net asset growth rate.
Kyntra Bio, Inc. - Total Liabilities Trend (2012–2025)
This chart illustrates how Kyntra Bio, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Kyntra Bio, Inc. to measure how efficiently the company converts operating cash flow to free cash.
Kyntra Bio, Inc. Competitors by Total Liabilities
The table below lists competitors of Kyntra Bio, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UCAL Limited
NSE:UCAL
|
India | Rs4.93 Billion |
|
Signetics Corporation
KQ:033170
|
Korea | ₩52.64 Billion |
|
Mega Perintis Tbk PT
JK:ZONE
|
Indonesia | Rp322.51 Billion |
|
Iconic Worldwide Bhd
KLSE:9113
|
Malaysia | RM116.25 Million |
|
Highest Performances Holdings Inc.
NASDAQ:HPH
|
USA | $1.64 Billion |
|
Ocean Vantage Holdings Bhd
KLSE:0220
|
Malaysia | RM20.33 Million |
|
Hamilton Global Opportunities PLC
PA:ALHGO
|
France | €5.46 Million |
|
NSC Groupe SA
PA:ALNSC
|
France | €38.26 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Kyntra Bio, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Kyntra Bio, Inc. market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 25.72 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.96 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kyntra Bio, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kyntra Bio, Inc. (2012–2025)
The table below shows the annual total liabilities of Kyntra Bio, Inc. from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $115.12 Million | -71.09% |
| 2024-12-31 | $398.16 Million | -32.02% |
| 2023-12-31 | $585.73 Million | -4.23% |
| 2022-12-31 | $611.57 Million | +12.27% |
| 2021-12-31 | $544.71 Million | +41.34% |
| 2020-12-31 | $385.39 Million | +19.69% |
| 2019-12-31 | $321.99 Million | -8.56% |
| 2018-12-31 | $352.13 Million | +11.36% |
| 2017-12-31 | $316.20 Million | +7.39% |
| 2016-12-31 | $294.44 Million | +7.56% |
| 2015-12-31 | $273.75 Million | +12.72% |
| 2014-12-31 | $242.85 Million | +28.26% |
| 2013-12-31 | $189.35 Million | +32.04% |
| 2012-12-31 | $143.40 Million | -- |
About Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible fact… Read more